logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Simple Partial Seizures

    Medications for Simple Partial Seizures

    FiltersReset Filters
    48 results

    • afinitor

      (everolimus)
      Novartis Pharmaceuticals Corporation
      Usage: AFINITOR is indicated for: advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women; progressive neuroendocrine tumors (PNET and non-functional GI/lung type); advanced renal cell carcinoma (RCC); TSC-associated renal angiomyolipoma; TSC-associated subependymal giant cell astrocytoma (SEGA); and partial-onset seizures related to TSC.

    • briviact

      (brivaracetam)
      UCB, Inc.
      Usage: BRIVIACT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older.

    • gabapentin

      (Gabapentin)
      TAGI Pharma, Inc.
      Usage: Gabapentin is indicated for managing postherpetic neuralgia in adults and as adjunctive therapy for partial onset seizures in adults and pediatric patients aged 3 years and older with epilepsy.

    • gabapentin

      (Gabapentin)
      Actavis Pharma, Inc.
      Usage: Gabapentin capsules are indicated for managing postherpetic neuralgia in adults and as adjunctive therapy for partial onset seizures in adults and pediatric patients aged 3 years and older with epilepsy.

    • gabapentin

      (Gabapentin)
      ScieGen Pharmaceuticals, Inc.
      Usage: Gabapentin is indicated for managing postherpetic neuralgia in adults and as adjunctive therapy for partial onset seizures in adults and pediatric patients aged 3 years and older with epilepsy.

    • gabapentin

      (Gabapentin)
      BioComp Pharma, Inc.
      Usage: Gabapentin oral solution is indicated for managing postherpetic neuralgia in adults and as adjunctive therapy for partial onset seizures in adults and pediatric patients aged 3 and older with epilepsy.

    • keppra

      (levetiracetam)
      UCB, Inc.
      Usage: KEPPRA is indicated for treating partial-onset seizures in patients aged 1 month and older. It is also approved as adjunctive therapy for myoclonic seizures in patients 12 years and older with juvenile myoclonic epilepsy and for primary generalized tonic-clonic seizures in patients 6 years and older with idiopathic generalized epilepsy.

    • lacosamide

      (lacosamide)
      Glenmark Pharmaceuticals Inc. USA
      Usage: Lacosamide tablets are indicated for treating partial-onset seizures in patients aged 4 years and older. Additional pediatric usage information exists but is not included on the label due to marketing exclusivity rights.

    • lacosamide

      (Lacosamide)
      Zydus Pharmaceuticals USA Inc.
      Usage: Lacosamide is indicated for the treatment of partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.

    • lacosamide

      (lacosamide)
      Sintetica US LLC
      Usage: Lacosamide Injection is indicated for the treatment of partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.